0.7056

2.96% 0.0203

Sangamo Therapeutics Inc (SGMO)

Overview News Price History Option Chain Financials Discussions Forecast

Sangamo Therapeutics Inc stock is traded at $0.7056, with a volume of 3.13M. It is up +2.96% in the last 24 hours and down -30.14% over the past month. Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Previous Close:

$0.6853

Open:

$0.6999

24h Volume:

3.13M

Relative Volume:

0.50

Market Cap:

$168.64M

Revenue:

$52.29M

Net Income/Loss:

$-134.84M

P/E Ratio:

-0.9408

EPS:

-0.75

Net Cash Flow:

$-117.11M

1W Performance:

-2.51%

1M Performance:

-30.14%

6M Performance:

-24.59%

1Y Performance:

+36.74%

1-Day Range:

$0.67

$0.7149

1-Week Range:

$0.67

$0.7835

52-Week Range:

$0.304

$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name

Sangamo Therapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

(510) 970-6000

Address

501 CANAL BLVD., RICHMOND, CA

Employee

183

Twitter

@sangamotx

Next Earnings Date

2025-03-17

Latest SEC Filings

SGMO's Discussions on Twitter

Compare SGMO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SGMO Sangamo Therapeutics Inc	0.7056	168.64M	52.29M	-134.84M	-117.11M	-0.75
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-13-24	Upgrade	Truist	Hold → Buy
Dec-10-24	Reiterated	H.C. Wainwright	Buy
Nov-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Apr-28-23	Downgrade	BofA Securities	Neutral → Underperform
Feb-27-23	Upgrade	Wedbush	Neutral → Outperform
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral
Jun-13-22	Resumed	Wedbush	Neutral
May-04-21	Initiated	RBC Capital Mkts	Outperform
Jan-07-21	Resumed	Guggenheim	Neutral
Jan-06-21	Initiated	Stifel	Hold
Dec-16-20	Resumed	H.C. Wainwright	Buy
Sep-08-20	Initiated	BofA Securities	Buy
Jul-07-20	Initiated	SunTrust	Buy
Aug-26-19	Initiated	H.C. Wainwright	Buy
Nov-14-18	Downgrade	JP Morgan	Overweight → Neutral
Nov-09-18	Downgrade	Guggenheim	Buy → Neutral
Oct-10-18	Initiated	Guggenheim	Buy
Jun-20-18	Initiated	BofA/Merrill	Buy
Nov-15-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-22-17	Resumed	Jefferies	Buy
Nov-01-16	Downgrade	Wedbush	Outperform → Neutral
Oct-19-16	Downgrade	Piper Jaffray	Overweight → Neutral
Dec-04-15	Initiated	Wells Fargo	Outperform
Oct-23-15	Resumed	Jefferies	Buy
May-03-13	Initiated	BioLogic Equity Research	Sell
Feb-23-11	Reiterated	JMP Securities	Mkt Outperform
Jul-29-10	Reiterated	Wedbush	Outperform
Oct-19-09	Initiated	Brean Murray	Sell
Oct-07-09	Reiterated	Leerink Swann	Outperform
Aug-25-09	Reiterated	JMP Securities	Mkt Outperform

View All

Sangamo Therapeutics Inc Stock (SGMO) Latest News

Apr 15, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System - Zenopa

Apr 15, 2025

Apr 13, 2025

Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy - insights.citeline.com

Apr 04, 2025

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (SGMO) - Seeking Alpha

Apr 04, 2025

Sangamo Thera enters critical deal with Lilly - The Pharma Letter

Apr 04, 2025

Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+ - BioSpace

Apr 04, 2025

Lilly throws lifeline to Sangamo with $1.4bn licensing deal - pharmaphorum

Apr 04, 2025

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga

Apr 04, 2025

Apr 03, 2025

RH, FIVE, SGMO, BAC, TSLA: Top 5 Trending Stocks TodayFive Below (NASDAQ:FIVE), Bank of America (NYSE:BAC) - Benzinga

Apr 03, 2025

Sangamo Therapeutics (SGMO) Signs Major Licensing Deal with Eli Lilly - GuruFocus

Apr 03, 2025

Sangamo Therapeutics (SGMO) Surges on Licensing Deal with Eli Li - GuruFocus

Apr 03, 2025

Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal By Investing.com - Investing.com South Africa

Apr 03, 2025

Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal - Investing.com Canada

Apr 03, 2025

Struggling Sangamo's brain-penetrating drug delivery tech attracts Eli Lilly in potential $1.4 billion pact - The Business Journals

Apr 03, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System - MarketScreener

Apr 03, 2025

Sangamo Therapeutics Stock Surges After The Bell: What's Going On? - Benzinga

Apr 03, 2025

Sangamo Signs Capsid License Deal With Eli Lilly; Shares Rise After Hours - MarketScreener

Apr 03, 2025

Sangamo Therapeutics stock soars on Lilly licensing deal By Investing.com - Investing.com South Africa

Apr 03, 2025

Sangamo Therapeutics stock soars on Lilly licensing deal - Investing.com

Apr 03, 2025

Apr 02, 2025